Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 8/20 | 0.70 |
| ▸ | MTNR1B | P49286 | 8/20 | 0.70 |
| ▸ | CA1 | P00915 | 3/20 | 0.67 |
| ▸ | CA2 | P00918 | 3/20 | 0.67 |
| ▸ | ACHE | P22303 | 3/20 | 0.67 |
| ▸ | DRD2 | P14416 | 7/20 | 0.60 |
| ▸ | DRD4 | P21917 | 5/20 | 0.60 |
| ▸ | DRD3 | P35462 | 4/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6513609 | 1.00 | MTNR1A (0.70) | MTNR1AMTNR1BCA1CA2ACHE | |
| SCHEMBL6516803 | 1.00 | MTNR1A (0.70) | MTNR1AMTNR1BCA1CA2ACHE | |
| SCHEMBL6518717 | 0.92 | MTNR1A (0.82) | MTNR1AMTNR1BCA1CA2ACHE | |
| SCHEMBL6518723 | 0.92 | MTNR1A (0.82) | MTNR1AMTNR1BCA1CA2ACHE | |
| SCHEMBL7021164 | 0.83 | MTNR1A (1.00) | MTNR1AMTNR1BCA1CA2ACHE | |
| SCHEMBL9731034 | 0.83 | MTNR1A (1.00) | MTNR1AMTNR1BCA1CA2ACHE | |
| SCHEMBL11960204 | 0.83 | MTNR1A (1.00) | MTNR1AMTNR1BCA1CA2ACHE | |
| SCHEMBL3390898 | 0.82 | MTNR1A (0.60) | MTNR1AMTNR1B | |
| SCHEMBL3392060 | 0.82 | MTNR1A (0.60) | MTNR1AMTNR1B | |
| SCHEMBL5522805 | 0.82 | MTNR1A (0.60) | MTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6949556-B2 | Acylated 1,2,3,4-tetrahydronaphthyl amines and their use as pharmaceutical agents | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-09-27 | — | — | US | disclosed |
| EP-1370530-A1 | ACYLATED 1,2,3,4-TETRAHYDRONAPHTHYL AMINES AND THEIR USE AS PHARMACEUTICAL | Aventis Pharma Deutschland GmbH (DE) | 2003-12-17 | — | — | EP | disclosed |
| US-20030022935-A1 | Acylated 1,2,3,4-tetrahydronaphthyl amines and their use as pharmaceutical agents | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2003-01-30 | — | — | US | disclosed |
| WO-2002064565-A1 | ACYLATED 1,2,3,4-TETRAHYDRONAPHTHYL AMINES AND THEIR USE AS PHARMACEUTICAL | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030022935-A1 | Acylated 1,2,3,4-tetrahydronaphthyl amines and their use as pharmaceutical agents | VEGFA, EDNRA, NR1H2 | MTNR1A 604/4885MTNR1B 448/4885CA1 2237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.